CMG Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
CMG Pharmaceutical's earnings have been declining at an average annual rate of -7.3%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 12.7% per year. CMG Pharmaceutical's return on equity is 3.4%, and it has net margins of 6.9%.
Key information
-7.3%
Earnings growth rate
-11.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 12.7% |
| Return on equity | 3.4% |
| Net Margin | 6.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How CMG Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 93,907 | 6,455 | 35,686 | 2,181 |
| 30 Sep 23 | 93,719 | 4,055 | 35,825 | 2,901 |
| 30 Jun 23 | 91,381 | 5,854 | 34,786 | 3,425 |
| 31 Mar 23 | 86,091 | 2,118 | 33,220 | 3,619 |
| 31 Dec 22 | 82,197 | -388 | 32,121 | 3,312 |
| 31 Mar 20 | 60,044 | 3,744 | 23,709 | 2,121 |
| 31 Dec 19 | 58,623 | 3,051 | 22,651 | 1,993 |
| 30 Sep 19 | 56,033 | 6,761 | 21,237 | 1,631 |
| 30 Jun 19 | 53,340 | 5,339 | 20,008 | 1,430 |
| 31 Mar 19 | 51,440 | 5,630 | 18,891 | 920 |
| 31 Dec 18 | 49,865 | 6,065 | 18,019 | 778 |
| 30 Sep 18 | 47,164 | 2,308 | 16,762 | 2,188 |
| 30 Jun 18 | 45,987 | 3,589 | 15,654 | 2,131 |
| 31 Mar 18 | 43,725 | 3,609 | 14,299 | 1,722 |
| 31 Dec 17 | 41,536 | 2,835 | 13,509 | 1,796 |
| 30 Sep 17 | 39,659 | 2,228 | 12,758 | 1,387 |
| 30 Jun 17 | 36,771 | 1,889 | 11,757 | 1,350 |
| 31 Mar 17 | 34,790 | 786 | 11,003 | 1,647 |
| 31 Dec 16 | 32,970 | 789 | 10,451 | 1,410 |
| 30 Sep 16 | 31,530 | -1,833 | 10,989 | 822 |
| 30 Jun 16 | 30,312 | -2,596 | 11,547 | 765 |
| 31 Mar 16 | 28,555 | -3,647 | 11,645 | 756 |
| 31 Dec 15 | 27,042 | -3,649 | 10,832 | 832 |
| 30 Sep 15 | 25,389 | -828 | 9,126 | 320 |
| 30 Jun 15 | 24,276 | -834 | 7,925 | 281 |
| 31 Mar 15 | 23,046 | -55 | 7,348 | 241 |
| 31 Dec 14 | 22,753 | 158 | 7,338 | 117 |
| 30 Sep 14 | 26,349 | 102 | 8,271 | 223 |
| 30 Jun 14 | 25,708 | 386 | 8,355 | 200 |
| 31 Mar 14 | 21,069 | 575 | 6,912 | 169 |
| 31 Dec 13 | 20,402 | 311 | 6,561 | 134 |
| 30 Sep 13 | 14,929 | -2,208 | 6,099 | 120 |
| 30 Jun 13 | 13,676 | -2,705 | 5,613 | 120 |
Quality Earnings: A058820 has a large one-off loss of ₩3.4B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: A058820 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A058820's earnings have declined by 7.3% per year over the past 5 years.
Accelerating Growth: A058820 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: A058820 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.1%).
Return on Equity
High ROE: A058820's Return on Equity (3.4%) is considered low.